Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Retained Earnings: 2016-2025

Historic Retained Earnings for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to -$118.1 million.

  • Collegium Pharmaceutical's Retained Earnings rose 33.11% to -$118.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$118.1 million, marking a year-over-year increase of 33.11%. This contributed to the annual value of -$164.0 million for FY2024, which is 29.67% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Retained Earnings stood at -$118.1 million, which was up 21.06% from -$149.6 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Retained Earnings registered a high of -$118.1 million during Q3 2025, and its lowest value of -$312.2 million during Q1 2021.
  • Moreover, its 3-year median value for Retained Earnings was -$185.9 million (2024), whereas its average is -$204.0 million.
  • Per our database at Business Quant, Collegium Pharmaceutical's Retained Earnings plummeted by 4,947.62% in 2021 and then spiked by 34.96% in 2024.
  • Over the past 5 years, Collegium Pharmaceutical's Retained Earnings (Quarterly) stood at -$256.3 million in 2021, then declined by 9.75% to -$281.3 million in 2022, then climbed by 17.12% to -$233.2 million in 2023, then grew by 29.67% to -$164.0 million in 2024, then soared by 33.11% to -$118.1 million in 2025.
  • Its Retained Earnings stands at -$118.1 million for Q3 2025, versus -$149.6 million for Q2 2025 and -$161.6 million for Q1 2025.